Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAFV600E mutation-prevalent area

被引:151
作者
Chung, Ki-Wook
Yang, Sun Kyung
Lee, Geon Kook
Kim, Eun Young
Kwon, Soim
Lee, Sang Hyun
Park, Do Joon
Lee, Hyun Sook
Cho, Bo Youn
Lee, Eun Sook
Kim, Sun Wook
机构
[1] Natl Canc Ctr, Res Inst & Hosp, Gyeonggi, South Korea
[2] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
关键词
D O I
10.1111/j.1365-2265.2006.02646.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Between 10 and 30% of the fine needle aspiration biopsies (FNABs) of thyroid nodules are diagnosed as 'indeterminate'. A molecular diagnostic method is needed to reduce unnecessary surgery in this group. In Korea, most thyroid cancer is the classic papillary type and the BRAF(V600E) mutation is highly prevalent. Aim To evaluate the role of pre-operative detection of BRAF(V600E) mutation in the FNAB specimens of thyroid nodules in a BRAF(V600E) mutation-prevalent geographical area. Patients and methods In 137 specimens of FNAB (107 papillary thyroid carcinomas (PTC); 3 follicular thyroid carcinomas (FTC); 2 undifferentiated thyroid carcinomas; 25 benign lesions), both direct DNA sequencing and PCR-RFLP were used for detecting the BRAF(V600E) mutation. The sensitivity and specificity were calculated. We analysed the association between BRAF(V600E) mutation and the clinico-pathological parameters. Results The BRAF(V600E) mutation was present in 93 (83%) of 112 thyroid cancers. Direct DNA sequencing showed a sensitivity of 83.0% and a specificity of 96.0%. The sensitivity and specificity of PCR-RFLP were 78.6% and 80.0%, respectively. Among 25 cases with indeterminate FNAB cytology, 8 patients had malignant lesions (5 PTC and 3 FTC). Three (60%) of 5 PTCs and 1 out of 17 benign lesions had BRAF(V600E) mutation (only one false positive case and the definitive pathology showed atypical nodular hyperplasia that could be a premalignant lesion). The diagnostic accuracy of this molecular method in only the 25 indeterminate nodules was 76% (19/25). No mutation was found in 3 FTCs. Among 107 PTCs, there was no significant association of the BRAF(V600E) mutation with the known risk factors. Conclusion Detection of the BRAF(V600E) mutation in FNAB specimens refines the FNAB-cytology diagnosis, especially in a BRAF(V600E) mutation-prevalent area. Direct DNA sequencing was a more reliable method than PCR-RFLP for detecting the BRAF(V600E) mutation with a high sensitivity and specificity.
引用
收藏
页码:660 / 666
页数:7
相关论文
共 29 条
[1]  
BERHO M, 1995, ANN CLIN LAB SCI, V25, P513
[2]   CELLULAR ADENOMATOID NODULES OF THE THYROID - REVIEW OF 219 FINE-NEEDLE ASPIRATES [J].
BUSSENIERS, AE ;
OERTEL, YC .
DIAGNOSTIC CYTOPATHOLOGY, 1993, 9 (05) :581-589
[3]  
Cáp J, 1999, CLIN ENDOCRINOL, V51, P509
[4]   Detection of RET/PTC oncogene rearrangements in Korean papillary thyroid carcinomas [J].
Chung, JH ;
Hahm, JR ;
Min, YK ;
Lee, MS ;
Lee, MK ;
Kim, KW ;
Nam, SJ ;
Yang, JH ;
Ree, HJ .
THYROID, 1999, 9 (12) :1237-1243
[5]   BRAF mutation in papillary thyroid carcinoma [J].
Cohen, J ;
Xing, MZ ;
Mambo, E ;
Guo, ZM ;
Wu, GG ;
Trink, B ;
Beller, U ;
Westra, WH ;
Ladenson, PW ;
Sidransky, D .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (08) :625-627
[6]   Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954
[7]   Pathologic features of Hashimoto's-associated papillary thyroid carcinomas [J].
Di Pasquale, M ;
Rothstein, JL ;
Palazzo, JP .
HUMAN PATHOLOGY, 2001, 32 (01) :24-30
[8]   Prevalence of Ras mutations in thyroid neoplasia [J].
Esapa, CT ;
Johnson, SJ ;
Kendall-Taylor, P ;
Lennard, TWJ ;
Harris, PE .
CLINICAL ENDOCRINOLOGY, 1999, 50 (04) :529-535
[9]   Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer [J].
Frattini, M ;
Ferrario, C ;
Bressan, P ;
Balestra, D ;
De Cecco, L ;
Mondellini, P ;
Bongarzone, I ;
Collini, P ;
Gariboldi, M ;
Pilotti, S ;
Pierotti, MA ;
Greco, A .
ONCOGENE, 2004, 23 (44) :7436-7440
[10]   Molecular classification of papillary thyroid carcinoma:: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis [J].
Giordano, TJ ;
Kuick, R ;
Thomas, DG ;
Misek, DE ;
Vinco, M ;
Sanders, D ;
Zhu, ZW ;
Ciampi, R ;
Roh, M ;
Shedden, K ;
Gauger, P ;
Doherty, G ;
Thompson, NW ;
Hanash, S ;
Koenig, RJ ;
Nikiforov, YE .
ONCOGENE, 2005, 24 (44) :6646-6656